ArmstrongA.W.SiegelM.P.BagelJ.From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis.J Am Acad Dermatol.2017 Feb; 76(2): 290–298. doi: 10.1016/j.jaad.2016.10.017. Epub 2016 Nov 28.
2.
CoatesL.C.Navarro-CoyN.BrownS.R.The TICOPA protocol (TIght COntrol of Psoriatic Arthritis): a randomised controlled trial to compare intensive management versus standard care in early psoriatic arthritis.BMC Musculoskelet Disord.2013 Mar 21;14: 101. doi: 10.1186/1471-2474-14-101.
3.
GulliverW.LyndeC.DutzJ.P.Think beyond the Skin 2014 Canadian Expert Opinion Paper on Treating to Target in Plaque Psoriasis.J Cutan Med Surg.2015 Jan-Feb; 19(1): 22–7. doi: 10.2310/7750.2014.13151. Epub 2015 Jan 1.
4.
MrowietzU.KragballeK.ReichK.Definition of treatment goals for moderate to severe psoriasis: a European consensus.Arch Dermatol Res.2011 Jan; 303(1): 1–10. doi: 10.1007/s00403-010-1080-1. Epub 2010 Sep 21.
5.
ArmstrongA.W.SchuppC.WuJ.BeboB.. Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003–2011.PLoS One.2012; 7(12): e52935. doi: 10.1371/journal.pone.0052935. Epub 2012 Dec 28.
6.
ArmstrongA.W.RobertsonA.D.WuJ.SchuppC.LebwohlM.G.. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011.JAMA Dermatol.2013 Oct; 149(10): 1180–5. doi: 10.1001/jamadermatol.2013.5264.
